Prudential Financial
ABUS icon

Prudential Financial’s Arbutus Biopharma ABUS Stock Holding History

Prudential Financial’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Buy
+23,310
New +$102K ﹤0.01% 2228
2025
Q4 		– Sell
-18,255
Closed -$82.9K – 2211
2025
Q3 		$82.9K Hold
18,255
– – ﹤0.01% 2293
2025
Q2 		$56.4K Buy
18,255
+7,610
+71% +$25.3K ﹤0.01% 2334
2025
Q1 		$37.2K Buy
+10,645
New +$35.5K ﹤0.01% 2220
2024
Q3 		– Sell
-14,975
Closed -$46.3K – 2706
2024
Q2 		$46.3K Buy
14,975
+2,390
+19% +$7.17K ﹤0.01% 2619
2024
Q1 		$32.5K Hold
12,585
– – ﹤0.01% 2626
2023
Q4 		$31.5K Buy
12,585
+1,220
+11% +$2.39K ﹤0.01% 2591
2023
Q3 		$23.1K Hold
11,365
– – ﹤0.01% 2567
2023
Q2 		$26.1K Hold
11,365
– – ﹤0.01% 2591
2023
Q1 		$34.4K Sell
11,365
-81,900
-88% -$231K ﹤0.01% 2530
2022
Q4 		$217K Buy
93,265
+58,900
+171% +$141K ﹤0.01% 2376
2022
Q3 		$65K Buy
34,365
+125
+0.4% +$294 ﹤0.01% 2542
2022
Q2 		$93K Sell
34,240
-422,420
-93% -$1.08M ﹤0.01% 2535
2022
Q1 		$1.36M Buy
456,660
+51,300
+13% +$157K ﹤0.01% 1734
2021
Q4 		$1.58M Buy
+405,360
New +$1.57M ﹤0.01% 1649

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prudential Financial's ABUS Position: Q1 2026 in Review

Prudential Financial opened a new position in Arbutus Biopharma (ABUS) in Q1 2026: 23,310 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #2228 among its holdings. This is a return to the name: Prudential Financial previously reported a position in ABUS as recently as Q3 2025.

Prudential Financial first reported a position in ABUS in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.58M in Q4 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Prudential Financial held 23,310 shares of Arbutus Biopharma worth $105K as of Q1 2026.
  • Arbutus Biopharma was a new Prudential Financial position in Q1 2026.
  • Arbutus Biopharma made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2228 holding.
  • Prudential Financial first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 15 quarters since.
  • Prudential Financial's Arbutus Biopharma position peaked at $1.58M in Q4 2021.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.